For combination studies, six primary AML samples were selected based on the presence of the most common favorable (e.g., NPM1) and unfavorable mutations (e.g., FLT3-internal tandem duplication (ITD) and KMT2A-PTD), in order to assess the efficacy of fadraciclib and its synergistic activity when combined with VEN, AraC, or AZA, towards these mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.